Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284434 | 0.97 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL19871771 | 0.97 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL17706429 | 0.83 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL16596861 | 0.81 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL14748126 | 0.80 | MC4R (0.36) | — | |
| SCHEMBL16596789 | 0.80 | — | — | |
| SCHEMBL15362951 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL10284279 | 0.79 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL10237649 | 0.78 | KDM4E (0.34) | SMN1; SMN2 | |
| SCHEMBL10237646 | 0.78 | SLC6A2 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052556-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LTD (IN) | 2021-02-25 | — | — | US | disclosed |
| EP-2389372-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2565193-A1 | Compositions and methods for inhibition of the JAK pathway | Rigel Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052556-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | SMN1; SMN2 3517/4885DPP4 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.